References1 The European Liver Patients Association.

April 2005.2 Centers for Disease Control and Prevention. Hepatitis B Frequently Asked Questions by. Available at: Accessed 08.12.053 World Health Organization. Hepatitis B Fact Sheet Number 204 Available at Accessed 08/12/054 Lavanchy D. J Viral Hepat. 2004 Mar 11 : 97-1075 World Health Organization. Expanded Program on Immunization Hepatitis B vaccine – making global progress. Available at Access 08.12.056 Robert Koch Institute. Quarter of 2006. Bulletin. November 2005 /# 46Novartis and Idenix Pharmaceuticals, announced today the European submission of telbivudine for approval as a a novel treatment for patients with chronic hepatitis B , a potentially fatal disease is estimated that over three million people affected worldwide are affected in Europe1 and over 350 million people..

Diabetic macular edema is the most common cause of vision loss in diabetic patients, especially those who are years younger than 60. Clinically significant DME occurs when neovascularization occurs and leaks in the central part of the retina. While standard of care, laser photocoagulation therapy is capable of disease progression, clinical studies with slower VEGF inhibitors have promising results with the potential to need to improve the vision of patients.– Create a new, nationwide health settlement of disputes protection of patients protecting patients and eliminate the runaway cost and risk of defensive medicine, the suppression of information on medical errors and lawsuits.